Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Naing

Showing results (271-280 of 397) with videos related to

Pageof 40
Sort By:
Investigational New Drugs|September 24, 2021
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory studyRony Dev, Linda L Zhong, Abdulrazzak Zarifa, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.
Molecular Cancer Therapeutics|July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted TherapeuticsJennifer J Wheler, Filip Janku, Aung Naing, et al.
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid TumorsAni S Balmanoukian, Jeffrey R Infante, Raid Aljumaily, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
Gynecologic Oncology|January 9, 2025
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancerJibran Ahmed, Bettzy Stephen, Muhammad R Khawaja, et al.
Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.
Pageof 40

Showing results (271-280 of 397) with videos related to

Sort By:
Pageof 40
Investigational New Drugs|September 24, 2021
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory studyRony Dev, Linda L Zhong, Abdulrazzak Zarifa, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.
Molecular Cancer Therapeutics|July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted TherapeuticsJennifer J Wheler, Filip Janku, Aung Naing, et al.
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid TumorsAni S Balmanoukian, Jeffrey R Infante, Raid Aljumaily, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
Gynecologic Oncology|January 9, 2025
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancerJibran Ahmed, Bettzy Stephen, Muhammad R Khawaja, et al.
Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.
Pageof 40